You are invited to attend 1 or more innovative CME/CE seminars offering expert guidance and interactive case discussion on current and emerging treatments for multiple myeloma. Topics include:
- Frontline Treatment of Multiple Myeloma: Current Options for Initial Therapy
- Relapsed/Refractory Multiple Myeloma: Assessment of Options for Subsequent Treatment
- Understanding Treatment Options for Special Patient Populations in Multiple Myeloma
Select the date and location that is most convenient for you. No program in your area? Call to see if your center could host a program (866-690-9902 or email registration@clinicaloptions.com).
Please register for these local live meetings and provide a case for discussion with the expert faculty. Click here to submit a patient case.
Program Overview
These CME/CE seminars provide expert guidance and interactive case discussion on current and emerging treatments for multiple myeloma in the frontline and relapsed settings, as well as important clinical considerations in special patient populations
Goal
The goal of this activity is to provide community-based clinicians with the opportunity for timely, engaging, and personalized education on the optimal treatment of multiple myeloma from initial diagnosis through refractory disease.
Target Audience
This activity is intended for community-based physicians, nurses, and other healthcare professionals who provide care for patients with multiple myeloma.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Compare the mechanisms of action of different classes of targeted agents for treating patients with multiple myeloma
- Evaluate the efficacy and safety of current and novel frontline therapies for the treatment of patients with multiple myeloma
- Analyze evolving evidence on the management of patients with relapsed/refractory multiple myeloma
- Differentiate frontline therapeutic approaches for multiple myeloma patients with comorbidities
- Review the treatment options for patients with multiple myeloma who are ineligible for transplantation because of age or renal insufficiency